HP Pro Tablet 408 G1 tablet was launched in January 2015. The tablet comes with a 8.00-inch display offering a resolution of 1280x800 pixels. HP Pro Tablet 408 G1 is powered by a 1.33GHz quad-core ...

Lenovo Tab P12 Pro tablet was launched on 8th September 2021. The tablet comes with a 12.60-inch touchscreen display offering a resolution of 2560x1600 pixels. Lenovo Tab P12 Pro is powered by an octa ...

Wacom has rocked the best drawing tablets market by announcing a complete redesign of its flagship Intuos Pro range. The Intuos Pro is a mainstay of the best Wacom tablets and with its new chip and ...

Concurrent with the development of a subcutaneous formulation, Viking is also developing an oral tablet formulation of VK2735, which the company believes could represent an attractive treatment ...

The best tablets of 2024 were the new iPad Pro M4 family, Apple's sleek and thin new iPad Pro models. Will 2025 be the year that Android tablets close the gap on Apple's premium tabs? We don't ...

Tablets are, effectively, computers. We benchmark tablets against common performance and graphics metrics and run battery life tests for video playback. But we also look at what tablets can do ...

So, read on for a recap of the best tablet deals I’ve spotted this Presidents’ Day. The 2024 iPad Pro 13-inch is the most powerful tablet money can buy, and thanks to this deal, you don’t ...

This post is brought to you by HUAWEI. The HUAWEI MatePad Pro 13.2 is a high-end tablet that aims to bridge the gap between tablets and PCs, offering a range of features designed to cater to ...

VKTX Price Action: According to data from Benzinga Pro, Viking Therapeutics shares are down 8.72% after hours at $30.58 on Wednesday.

Based on these results, Viking designed and recently initiated a Phase 2 trial called the VENTURE-Oral Dosing trial to evaluate longer-term dosing with the tablet formulation in subjects with obesity.

In this article, we are going to take a look at where Viking Therapeutics Inc ... VKTX initiated the phase 2 clinical trial of the oral tablet formulation of VK2735 in January this year, testing ...